Clinical Trials

ALCHEMIST A081105 E4512 A151216

ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Objective

A081105, Randomized Double-Blind Placebo-Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

E4512, A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A151216, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Clinical Trial Categories

  • Lung Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at (603) 224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: (603) 230-6000